Ligand Pharmaceuticals (LGND) Income from Discontinued Operations (2010 - 2016)
Ligand Pharmaceuticals (LGND) reported Income from Discontinued Operations of 731000.0 for Q1 2016, down 69.5% sequentially from 2397000.0 in Q2 2013.
Ligand Pharmaceuticals (LGND) Income from Discontinued Operations (2010 - 2016) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 5 years of Income from Discontinued Operations data on file, last reported at 731000.0 in Q1 2016.
- For the quarter ending Q1 2016, Income from Discontinued Operations changed N/A year-over-year to 731000.0; the trailing twelve-month figure through Mar 2017 stood at 731000.0 (changed 0.0% YoY), and the FY2013 full-year result was 2588000.0, up 20.54% from the prior year.
- Income from Discontinued Operations slipped to 731000.0 in Q1 2016, from 2397000.0 in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of 2397000.0 in Q2 2013 to a low of 1523000.0 in Q4 2012.
- A 3-year average of 911000.0 and a median of 1265000.0 in 2012 frame the typical range for Income from Discontinued Operations.
- Across the five-year window, Income from Discontinued Operations surged 46675.0% in 2012 and tumbled 89.79% in 2013, its largest moves.
- Tracing LGND's Income from Discontinued Operations over 3 years: stood at 1523000.0 in 2012, then jumped by 257.39% to 2397000.0 in 2013, then slumped by 69.5% to 731000.0 in 2016.
- Business Quant data shows LGND's Income from Discontinued Operations at 731000.0 in Q1 2016, 2397000.0 in Q2 2013, and 191000.0 in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | - |
| 10 | Ligand Pharmaceuticals | 5.90 Bn | 5.12 Bn | 48.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 731,000.00 |
| Jun 30, 2013 | 2.40 Mn |
| Mar 31, 2013 | 191,000.00 |
| Dec 31, 2012 | -1.52 Mn |
| Jun 30, 2012 | 1.80 Mn |
| Mar 31, 2012 | 1.87 Mn |
| Sep 30, 2011 | -1,000.00 |
| Mar 31, 2011 | 4,000.00 |
| Dec 31, 2010 | 2.16 Mn |
| Sep 30, 2010 | 12,000.00 |
| Jun 30, 2010 | 7,000.00 |